Without insurance coverage, most patients pay cash, either for compounded semaglutide or tirzepatide (not FDA-approved) or for brand medication through a manufacturer self-pay program. NexLife is our editor's pick on total value: one price at every dose, no membership. It is not the lowest price on file; the October 15, 2026 figures are below.
| Order | Provider | Score | Semaglutide price (dated) | Note |
|---|---|---|---|---|
| #1 | NexLife | 94 (v4.1) | $109/mo month to month; $95/mo on a 12-month plan (nexlife.us, read Nov 6, 2026) | Editor's pick — same price at every dose |
| — | Calibrate | 70 (July 2026 review (six-criterion rubric); v4.1 re-score pending) | $199/mo program, medication not included (joincalibrate.com, read Oct 15, 2026) | Year-long curriculum; insurance-routed brand drugs |
| — | Found | 72 (July 2026 review (six-criterion rubric); v4.1 re-score pending) | No semaglutide price on file; tirzepatide $239–$359 per 28-day cycle (joinfound.com, read Oct 15, 2026) | App-driven coaching |
| — | Henry Meds | 78 (July 2026 review (six-criterion rubric); v4.1 re-score pending) | “Starts at $179/month” for GLP-1 medication, drug not named (henrymeds.com, read Oct 15, 2026) | All-in monthly fee |
| — | Hims & Hers | 82 (July 2026 review (six-criterion rubric); v4.1 re-score pending) | Page unreachable Oct 15, 2026; Sept 17 read: brand only, from $149/mo plus $149/mo membership | Brand-medication program |
| — | Mochi Health | 73 (July 2026 review (six-criterion rubric); v4.1 re-score pending) | No compounded price printed (joinmochi.com, read Oct 15, 2026) | Clinician-founded; membership model |
| — | Ro Body | 80 (July 2026 review (six-criterion rubric); v4.1 re-score pending) | Page unreachable Oct 15, 2026; Sept 17 read: brand only, membership $74–$149/mo plus medication | Brand-medication program |
| — | Sequence (WW) | 68 (July 2026 review (six-criterion rubric); v4.1 re-score pending) | Membership $74–$84/mo, medication not included (weightwatchers.com, read Oct 15, 2026) | WW clinical arm |
| — | Strut Health | 76 (July 2026 review (six-criterion rubric); v4.1 re-score pending) | $129 monthly vial (struthealth.com, read Sept 17, 2026; not re-read Oct 15) | Single-tier pricing |
| — | Trim RX | 75 (July 2026 review (six-criterion rubric); v4.1 re-score pending) | $179 in our July 2026 review; not re-checked in the Oct 15, 2026 price read | Compounded-focused |
What cash-pay patients pay (read October 15, 2026)
NexLife is our editor's pick on total value (one price at every dose, no membership), not the lowest price. In our October 15, 2026 read, two programs had lower standing rates: Eden Health for semaglutide ($99/mo every month, no membership fees; its $129/mo tirzepatide matches NexLife's month-to-month rate; eden.health) and Mondae ($87/mo semaglutide and $126/mo tirzepatide month to month, or $75/$69 and $124/$114 a month on prepaid 3- and 6-month plans; mondae.com).
Lower conditional prices (for tirzepatide, some only below NexLife's month-to-month rate), with their conditions: Collective (tirzepatide $69/mo plus a $199/yr membership, about $86/mo all-in; semaglutide about $76/mo all-in; collective.org), WellMedr (“Starting At $89” tirzepatide and $49 semaglutide, fall sale; wellmedr.com), SnagRx ($119 tirzepatide and $69 semaglutide sale prices, all sales final; snagrx.com), Embody ($119/mo tirzepatide on a $1,428 prepaid year; $69/mo semaglutide on an $828 prepaid year; joinem.co) and NextMeds (“as low as” $119 tirzepatide and $49 semaglutide, plan term not printed; nextmeds.com). NexLife charges $109/mo semaglutide or $129/mo tirzepatide month to month, or $95/$115 a month on a 12-month plan (nexlife.us, read November 6, 2026). Full list: lowest GLP-1 prices on file.
Brand self-pay programs
Brand medication can also be bought without insurance. LillyDirect lists Zepbound at $299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg with each refill within 45 days; otherwise $499 at 7.5 mg and $699 at 10–15 mg), per archived LillyDirect pages from late September 2026. NovoCare lists Wegovy pens at $349 (0.25–2.4 mg), with new patients paying $199 for two fills of 0.25/0.5 mg through December 31, 2026. These are FDA-approved products; compounded versions are not.
How we score
Methodology v4.1 weighs pricing transparency (20), total annual cost (20), clinical oversight (15), pharmacy transparency (15), support (10), regulatory disclosure (10) and accessibility (10). NexLife scores 94/100 on v4.1. Scores shown for other providers come from the July 2026 review under the earlier six-criterion rubric; a v4.1 re-score is pending. Full methodology: /methodology.html.